Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Allbloc | 1 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 4011.70 | NCE · Prescription | Boston Oncology Arabia | Valid |
| Clofarabine Ratiopharm | 1 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 1737.10 | Generic · Prescription | Ratiopharm GmbH | Valid |
| Evoltra | 1 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 4011.70 | NCE · Prescription | GENZYME EUROPE B.V. | Valid |
| Retebin | 1 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 3811.10 | Generic · Prescription | Pharma Pharmaceutical Industries (PPI) | Valid |
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | DR REDDYS | Prescription | 6 Nov 2017 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | AMNEAL | Prescription | 6 Nov 2017 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | MSN | Prescription | 6 Dec 2017 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | GLAND | Prescription | 31 Oct 2018 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | ACCORD HLTHCARE | Prescription | 22 Feb 2019 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | MEITHEAL | Prescription | 23 Oct 2020 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | SCINOPHARM TAIWAN | Prescription | 3 Jan 2025 |
| CLOLAR | 20MG/20ML (1MG/ML) | solution · intravenous | GENZYME | Discontinued | 28 Dec 2004 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | MLV | Discontinued | 9 May 2017 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | PHARMOBEDIENT | Discontinued | 6 Nov 2017 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | INGENUS PHARMS LLC | Discontinued | 14 Sep 2018 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | HOSPIRA | Discontinued | 27 Dec 2018 |
| CLOFARABINE | 20MG/20ML (1MG/ML) | solution · intravenous | EUGIA PHARMA | Discontinued | 3 Oct 2022 |
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ? 21 years old at initial diagnosis.
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ? 21 years old at initial diagnosis.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CLOLAR | 02330407 | 1 MG / ML | SOLUTION · INTRAVENOUS | SANOFI-AVENTIS CANADA INC |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.